Ground-breaking work creates novel oil-in-water nanoemulsions
New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.
Particle Technology is an important discipline that underpins many industrial sectors, including biomedical applications, latex paints and coatings, engine oil additives, viscosity modifiers and emulsion stabilisation. Steve Armes, Professor of Polymer and Colloid Chemistry at the University of Sheffield, is one of the UK's leading experts in particle science and technology, with more than 30 years of research experience in this field. In particular, he designs a wide range of microscopic polymer particles on the nanoscale.
Professor Steve Armes said: "It is well known that oil and water do not mix. Similarly, the incorporation of oil droplets within inorganic crystals is highly counter-intuitive because there is a large difference in surface energy for these two components. Our new occlusion protocol, developed using the high-pressure LV-1 microfluidizer, has enabled either oil-soluble dyes or oil-dispersible hydrophobic nanoparticles to be incorporated for the first time within host crystals. This exciting new innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives for various commercial applications. In view of this, we have filed a preliminary patent application to protect the IP associated with our work.
Professor Ames added: “We are indebted to the excellent technical support provided by Analytik, which has enabled us to fully exploit the high-pressure LV-1 Microfluidizer for the production of well-defined nanoemulsions. We will be seeking their support and advice in the future as we seek to extend our studies to include water-in-oil nanoemulsions.”
The LV1 Microfluidizer is a high shear homogeniser which brings outstanding processing capabilities to samples as small as 1 mL. The LV1 has been designed to achieve operating pressures up to 30,000 psi for samples ranging from 1-6 mL. Using proprietary fixed-geometry interaction chamber technology, the LV1 is capable of processing a wide variety of fluids such as oil-in-water emulsions, solids-in-liquid suspensions, and cells, including the most difficult yeasts and plant cells, in as few as 1-2 passes. What's more, the process is repeatable and is guaranteed to scale up to pilot and/or production volumes.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance